Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.

MLA

Mahnashi, Mater H., et al. “Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.” Pharmaceuticals (14248247), vol. 15, no. 2, Feb. 2022, p. 246. EBSCOhost, https://doi.org/10.3390/ph15020246.

APA

Mahnashi, M. H., El-Senduny, F. F., Alshahrani, M. A., & Abou-Salim, M. A. (2022). Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition. Pharmaceuticals (14248247), 15(2), 246. https://doi.org/10.3390/ph15020246

Chicago

Mahnashi, Mater H., Fardous F. El-Senduny, Mohammed Abdulrahman Alshahrani, and Mahrous A. Abou-Salim. 2022. “Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.” Pharmaceuticals (14248247) 15 (2): 246. doi:10.3390/ph15020246.